Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Acquired by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. increased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 20.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 201,304 shares of the specialty pharmaceutical company’s stock after acquiring an additional 33,948 shares during the quarter. Robeco Institutional Asset Management B.V. owned about 0.33% of Jazz Pharmaceuticals worth $24,791,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Algert Global LLC acquired a new stake in shares of Jazz Pharmaceuticals during the second quarter worth about $637,000. Creative Planning increased its position in Jazz Pharmaceuticals by 21.7% during the second quarter. Creative Planning now owns 3,819 shares of the specialty pharmaceutical company’s stock worth $408,000 after buying an additional 680 shares during the period. Sanctuary Advisors LLC purchased a new stake in Jazz Pharmaceuticals in the second quarter valued at approximately $213,000. SG Americas Securities LLC acquired a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at approximately $752,000. Finally, GAMMA Investing LLC grew its position in shares of Jazz Pharmaceuticals by 41.3% during the third quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock worth $46,000 after acquiring an additional 121 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 2,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $121.17, for a total transaction of $242,340.00. Following the completion of the transaction, the chief executive officer now directly owns 427,025 shares in the company, valued at approximately $51,742,619.25. This trade represents a 0.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total transaction of $456,617.00. Following the transaction, the executive vice president now owns 33,048 shares of the company’s stock, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 7,253 shares of company stock valued at $890,594 in the last quarter. 4.20% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on JAZZ shares. Royal Bank of Canada reiterated an “outperform” rating and set a $179.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Piper Sandler reiterated an “overweight” rating and set a $163.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Friday, November 22nd. Finally, TD Cowen dropped their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $177.00.

Jazz Pharmaceuticals Stock Up 0.6 %

JAZZ stock opened at $125.05 on Friday. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $134.17. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The company has a market cap of $7.56 billion, a P/E ratio of 17.61, a P/E/G ratio of 0.87 and a beta of 0.56. The company’s 50-day moving average price is $122.74 and its 200 day moving average price is $115.83.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.